Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

doi:10.1097/QAD.0b013e328341b86a

. 2011 Jan 28;25(3):385-7.

doi: 10.1097/QAD.0b013e328341b86a.

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

Maria Salgado¹, Gregory D Kirk, Andrea Cox, Alleluiah Rutebemberwa, Yvonne Higgins, Jacquie Astemborski, David L Thomas, Chloe L Thio, Mark S Sulkowski, Joel N Blankson

Affiliations

PMID: 21099664
PMCID: PMC3158988
DOI: 10.1097/QAD.0b013e328341b86a

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

Maria Salgado et al. AIDS. 2011.

. 2011 Jan 28;25(3):385-7.

doi: 10.1097/QAD.0b013e328341b86a.

Authors

Maria Salgado¹, Gregory D Kirk, Andrea Cox, Alleluiah Rutebemberwa, Yvonne Higgins, Jacquie Astemborski, David L Thomas, Chloe L Thio, Mark S Sulkowski, Joel N Blankson

Affiliation

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

PMID: 21099664
PMCID: PMC3158988
DOI: 10.1097/QAD.0b013e328341b86a

Abstract

We tested the hypothesis that a single nucleotide polymorphism (SNP) located near the interleukin-28B gene is associated with the control of hepatitis C virus and HIV-1 replication in elite controllers/suppressors. We show here that the protective genotype is not overrepresented in elite controllers/suppressors compared with HIV-1-seronegative patients and HIV-1-infected patients with viral loads more than 10 000 copies/ml. Thus, it appears that this SNP is not associated with the elite control of HIV-1 infection.

PubMed Disclaimer

Cited by

IL28B genotype does not correlate with HIV control in African Americans.
Sajadi MM, Shakeri N, Talwani R, Howell CD, Pakyz R, Redfield RR, Parsa A. Sajadi MM, et al. Clin Transl Sci. 2011 Aug;4(4):282-4. doi: 10.1111/j.1752-8062.2011.00307.x. Clin Transl Sci. 2011. PMID: 21884517 Free PMC article.
Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.
Chinnaswamy S. Chinnaswamy S. Genes Immun. 2016 Jul;17(5):265-75. doi: 10.1038/gene.2016.24. Epub 2016 Jun 9. Genes Immun. 2016. PMID: 27278127 Free PMC article. Review.
Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.
Asher AK, Santos GM, Evans J, Dokubo EK, Lee TH, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, Page K. Asher AK, et al. AIDS. 2013 Nov 13;27(17):2691-6. doi: 10.1097/01.aids.0000433242.86362.21. AIDS. 2013. PMID: 23939233 Free PMC article.
HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.
Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, Gonzalez-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, Leal M, Lichterfeld M, Ruiz-Mateos E; ECRIS integrated in the Spanish AIDS Research Network. Dominguez-Molina B, et al. Clin Infect Dis. 2017 Mar 1;64(5):621-628. doi: 10.1093/cid/ciw833. Epub 2016 Dec 16. Clin Infect Dis. 2017. PMID: 27986689 Free PMC article.
Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.
Jõgeda EL, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, Uusküla A, Toompere K, Lutsar I, Huik K. Jõgeda EL, et al. J Med Virol. 2018 Nov;90(11):1779-1783. doi: 10.1002/jmv.25258. Epub 2018 Aug 16. J Med Virol. 2018. PMID: 29992584 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–F29. - PMC - PubMed
1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. - PubMed
1. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801. - PMC - PubMed
1. Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85:295–302. - PMC - PubMed
1. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009;9:55–69. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

[1] Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–F29. - PMC - PubMed

[2] Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–F29. - PMC - PubMed

[3] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. - PubMed

[4] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. - PubMed

[5] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801. - PMC - PubMed

[6] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801. - PMC - PubMed

[7] Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85:295–302. - PMC - PubMed

[8] Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85:295–302. - PMC - PubMed

[9] Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009;9:55–69. - PMC - PubMed

[10] Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009;9:55–69. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

Affiliation

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical